智通财经网·2025-10-30 11:21Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a decline in revenue and net profit for the first three quarters of 2025, indicating challenges in the market [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was 0.957 billion yuan, down 10.18% year-on-year [1] - Basic earnings per share stood at 1.72 yuan [1] Quarterly Results - In the third quarter of 2025, the company recorded a revenue of 18.328 billion yuan, reflecting a year-on-year decline of 1.89% [1] - The net profit attributable to shareholders for the third quarter was 0.291 billion yuan, a decrease of 9.58% year-on-year [1]